Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

SUMMARY: Persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium found that persistence with denosumab remains consistently high after 24 months in patients at high risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahrleitner-Pammer, A., Papaioannou, N., Gielen, E., Feudjo Tepie, M., Toffis, C., Frieling, I., Geusens, P., Makras, P., Boschitsch, E., Callens, J., Anastasilakis, A. D., Niedhart, C., Resch, H., Kalouche-Khalil, L., Hadji, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486684/
https://www.ncbi.nlm.nih.gov/pubmed/28643265
http://dx.doi.org/10.1007/s11657-017-0351-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486684/
https://www.ncbi.nlm.nih.gov/pubmed/28643265
http://dx.doi.org/10.1007/s11657-017-0351-2

Ejemplares similares